Activities of Heidi HAUTALA related to 2020/2071(INI)
Legal basis opinions (0)
Amendments (4)
Amendment 26 #
Draft opinion
Paragraph 3
Paragraph 3
3. Emphasises that the EU is a leading global exporter of pharmaceutical products; notes that the protection and enforcement of IP rights in free trade agreements (FTAs) and at the WTO is crucial to the development of newa balance must be struck between encouraging innovation, ensuring access to medicines, and treatmentsprotecting public health; underlines that the flexibilities provided in the TRIPS agreement canshould be used to address potential supply shortages in exceptional circumstances;
Amendment 43 #
Draft opinion
Paragraph 4
Paragraph 4
4. Emphasises that a broad network of FTAs together with a functioning multilateral trading system constitute the best way of guaranteeing that multiple sources of manufacturing for essential medicines are available and regulatory standards converge globallykeeping all options open to ensure the adequate availability of needed pharmaceuticals, including by authorising the import of medicines produced abroad under compulsory licenses, is the best way of guaranteeing that multiple sources of manufacturing for essential medicines are available and regulatory standards converge globally; calls on the EU to provide for exception clauses in European rules on data- and market exclusivity so that Member States can effectively use compulsory licenses;
Amendment 46 #
Draft opinion
Paragraph 5
Paragraph 5
5. Strongly encourages all countries to joinTakes notes of recent proposals to extend the scope of the WTO’s Pharmaceutical Tariff Elimination Agreement; calls for its scope to be extended to allfuture negotiations to respect the policy space of all countries in order to ensure their strategic autonomy and the access of their citizens to pharmaceutical and medicinal products; stresses that medical products should be exempted from retaliation in trade disputes;
Amendment 62 #
Draft opinion
Paragraph 6
Paragraph 6
6. Underlines that a complete repatriation of medical supply chains is not possible in a global economy; urges the Commission and the Member States to work with the EU’s partners, the WHO and WTO, on establishing an international framework that can prevent the breakdown of supply chains and limit resort to protectionistdamaging measures during health crises.